AGA Expert Exchange: Biosimilars in GI educational program was designed to educate and inform health care providers of the safety and efficacy of biosimilars and how to appropriately incorporate biosimilars into clinical practice. The program is a blended learning approach hosted on AGA’s twitter account and the AGA Community. Check out our enduring module with highlights from the live Twitter chat along with additional videos and resources on the application of biosimilars in GI. This program is accredited for 1 AMA PRA Category 1 Credit.
Sign in to access
After you sign in, please click the "Launch" button on the top of this page to access the course.
AGA Expert Exchange included the following components:
Event 1: Biosimilars: Back to the Basics Tweetorial
Posted on AGA’s Twitter feed (@AmerGastroAssn) on behalf of program faculty, Jami Kinnucan, MD, and Florian Rieder, MD, this event kicks-off the program with an introductory summary of biosimilars. Please review the content before attending AGA’s live twitter chat. Content includes:
- What is a biosimilar
- Difference between biosimilars and generics
- How biosimilars are made
- The US FDA approval process
- Currently approved biosimilars in IBD
To see the archived twitter chat, please use the link:
#AGAExpertX
Event 2: Live Twitter Chat – Tuesday, Dec. 7, 2021
AGA (@AmerGastroAssn) kicked-off the discussion, and experts created a chain of discussions using the hashtag #AGAExpertX. The live-tweeting event provided participants the opportunity to directly engage in a discussion with their peers and the subject matter experts. Faculty presented specific case challenges using polls during the live twitter chat and leave time for open Q&A. Unanswered questions or additional questions were posted on the AGA community in an enduring roundtable discussion.
Event 3: AGA Community Roundtable panel discussion – Tuesday, Dec. 14-Tuesday, Dec. 21
Drs. Kinnucan and Rieder moderated the discussion by initiating case-based questions to give members and opportunity to apply the guidance and practices covered in the Tweetorial and Twitter Chat. AGA Community Roundtable panel discussion from Dec. 14 through Dec. 21 (PDF).
Faculty:
Anita Afzali MD, MPH, AGAF
Ohio State University Wexner Medical Center
Jana G. Al Hashash, MD, MS
Mayo Clinic Jacksonville, FL
Shubha Bhat, PharmD, MS
Boston University School of Medicine
Raymond K. Cross, MD, MS, AGAF
University of Maryland
Jami Kinnucan, MD (Chair)
University of Michigan Health
Florian Rieder, MD (Chair)
Cleveland Clinic
Learning Objectives:
- Understand safety and efficacy for biosimilar development and approval processes.
- Evaluate how to appropriately incorporate biosimilars into clinical practice.
- Discuss recent and emerging clinical trial data for newly approved biosimilars.
Accreditation Statement
The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.
The AGA Institute designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Jan. 27, 2023
Disclosures
Raymond K. Cross, MD, MS, AGAF
Consulting: Abbvie, Eli Lilly, LabCorp, Samsung bioepis
Advisory Committee/Review Panel: Abbvie, Bristol Myers Squibb, Janssen, Takeda, Pfizer
Shubha Bhat, PharmD, MS, BCACP
No financial relationship with an ineligible company
Jana Al Hashash, MD, MSc
No financial relationship with an ineligible company
Anita Afzali, MD, MPH, AGAF
Consulting: Janssen. AbbVie, Takeda, Pfizer, Bristol Myers Squibb, Eli Lilly, Gilead
Advisory Committee/Review Panel: TLL Pharmaceuticals, DiaSorin
Jami Kinnucan, MD
Advisory Committee/Review Panel: Pfizer, bMS, Janssen
Florian Rieder, MD
Consulting: Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, 89Bio
